- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Media Contact
Monheim, July 4, 2018 – Bayer Animal Health GmbH and Mitsui Chemicals Agro, Inc. (MCAG) have signed a global license agreement to advance innovative parasiticides for companion animals based on MCAG’s innovation and technology. As part of the license agreement, Bayer will develop and commercialize novel compounds based on intellectual property from MCAG. Further terms of the agreement were not disclosed.
Pet ownership is growing around the world and with that customers’ requirement for effective and convenient protection from parasites. “At Bayer, we passionately care for the health and well-being of animals,” said Dr. Dirk Ehle, Head of Bayer Animal Health. “And we have long been committed to help pet owners protect their animals from parasites. Today we have taken an important next step to further deliver on this commitment to our customers.”
Dr. Sabine Bongaerts, Head of Drug Discovery within Bayer Animal Health, added: “This license agreement combines the strong science base within Bayer with innovative chemistry from MCAG. It will enable us to further expand our strong portfolio of parasiticides in the companion animal sector and deliver new compelling products to our customers.”
Mr. Satoshi Ozawa, President and CEO of MCAG said: “Under the concept of Technology and Innovation, MCAG has been providing its innovative products and services to the customers in agrochemicals and environmental health businesses for many years so far. Now, through close and successful collaboration with Bayer in the animal health sector, we are excited about this new opportunity to have our innovation work for another horizon of companion animal business.”
About Mitsui Chemicals
Mitsui Chemicals (Tokyo: 4183, ISIN: JP3888300005), which traces its roots back to 1912, has an annual sale of 1,300 billion yen in the fiscal year ending March 2018 and more than 130 companies with over 17,000 employees in 28 countries. As one of Japan’s leading chemical companies, Mitsui Chemicals contributes broadly to society by providing high-quality products and services to customers through innovations and creation of materials and products while keeping in harmony with the global environment. Its business portfolio includes materials for next-generation mobility, healthcare services, packaging, agrochemicals, electronic materials, and environment and energy sector. Mitsui Chemicals will continue to contribute to solving social challenges with its state-of-the-art technology and by "Creating New Customer Value through Innovation". Mitsui Chemicals’ global agrochemical business is operated by its 100% subsidiary, Mitsui Chemicals Agro, Inc., who supplies innovative agrochemicals for crop protection and pest management. With a customer-centric point of view, The Company offers unique and effective products and services, and contributes to the sustainable, productive agriculture. Latest group news can be found at https://www.mitsuichem.com/en/.
Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of 35.0 billion euros. Capital expenditures amounted to 2.4 billion euros, R&D expenses to 4.5 billion euros. For more information, go to www.bayer.com.
Find more information at animalhealth.bayer.com
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.